Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)

Next Previous
X
Search
Trial Profile

A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms LIMMITLESS
  • Sponsors AbbVie; AbbVie Germany

    • Most Recent Events

    • 01 May 2024 Results of Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks, published in the Journal of the European Academy of Dermatology and Venereology
    • 12 Mar 2024 Results of subgroup analysis assessing Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks presented at the American Academy of Dermatology annual Meeting 2024
    • 12 Mar 2024 Interim Results of safety (data cutoff May 22, 2023) efficacy through 304 weeks of continuous risankizumab treatment, presented at the American Academy of Dermatology annual Meeting 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top